Business
The Opthea (ASX:OPT) share price up after receiving FDA approval
The Opthea Ltd (ASX: OPT) share price is up 8.39% to $1.55 this morning. The rise comes after receiving an initial Pediatric Study Plan (iPSP) waiver from the US Food and Drug Administration (FDA) for OPT-302.
Opthea is committed to improving vision in patients suffering from retinal eye diseases. OPT-302 is the company’s lead product candidate. The product also has the potential to address the unmet medical need within the eye disease market.
Another milestone for the Opthea share price
An iPSP is a pre-requisite for a marketing application of new medicine for a biopharmaceutical company in the US. Additionally, the iPSP provides the…
-
Noosa News16 hours agoPrincess Anne is coming to Australia. Here’s what we know of her plans
-
General5 hours agoCommunity devastated after freight train kills one-year-old girl near Narrabri
-
General21 hours agoPolish woman found guilty of harassing Maddie McCann’s parents, but acquitted for stalking
-
General19 hours agoTravellers face cancelled flights over US shutdown